Harrow (HROW) Competitors $31.14 -0.41 (-1.28%) As of 02:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HROW vs. ZLAB, AKRO, PBH, PTCT, CYTK, RYTM, ACAD, MRUS, PRGO, and RNAShould you be buying Harrow stock or one of its competitors? The main competitors of Harrow include Zai Lab (ZLAB), Akero Therapeutics (AKRO), Prestige Consumer Healthcare (PBH), PTC Therapeutics (PTCT), Cytokinetics (CYTK), Rhythm Pharmaceuticals (RYTM), ACADIA Pharmaceuticals (ACAD), Merus (MRUS), Perrigo (PRGO), and Avidity Biosciences (RNA). These companies are all part of the "medical" sector. Harrow vs. Its Competitors Zai Lab Akero Therapeutics Prestige Consumer Healthcare PTC Therapeutics Cytokinetics Rhythm Pharmaceuticals ACADIA Pharmaceuticals Merus Perrigo Avidity Biosciences Harrow (NASDAQ:HROW) and Zai Lab (NASDAQ:ZLAB) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability. Do analysts recommend HROW or ZLAB? Harrow currently has a consensus target price of $61.40, suggesting a potential upside of 96.89%. Zai Lab has a consensus target price of $47.37, suggesting a potential upside of 31.21%. Given Harrow's stronger consensus rating and higher probable upside, equities analysts plainly believe Harrow is more favorable than Zai Lab.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Harrow 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Zai Lab 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Do institutionals & insiders have more ownership in HROW or ZLAB? 72.8% of Harrow shares are owned by institutional investors. Comparatively, 41.7% of Zai Lab shares are owned by institutional investors. 15.2% of Harrow shares are owned by company insiders. Comparatively, 5.0% of Zai Lab shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more volatility and risk, HROW or ZLAB? Harrow has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500. Comparatively, Zai Lab has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Does the media favor HROW or ZLAB? In the previous week, Zai Lab had 7 more articles in the media than Harrow. MarketBeat recorded 11 mentions for Zai Lab and 4 mentions for Harrow. Harrow's average media sentiment score of 1.11 beat Zai Lab's score of 0.54 indicating that Harrow is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harrow 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zai Lab 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is HROW or ZLAB more profitable? Harrow has a net margin of -10.19% compared to Zai Lab's net margin of -60.26%. Harrow's return on equity of -25.01% beat Zai Lab's return on equity.Company Net Margins Return on Equity Return on Assets Harrow-10.19% -25.01% -4.27% Zai Lab -60.26%-33.35%-23.28% Which has higher valuation and earnings, HROW or ZLAB? Harrow has higher earnings, but lower revenue than Zai Lab. Harrow is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHarrow$199.61M5.73-$17.48M-$0.56-55.69Zai Lab$398.99M9.98-$257.10M-$2.49-14.50 SummaryHarrow beats Zai Lab on 11 of the 16 factors compared between the two stocks. Get Harrow News Delivered to You Automatically Sign up to receive the latest news and ratings for HROW and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HROW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HROW vs. The Competition Export to ExcelMetricHarrowMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.14B$2.43B$5.42B$8.81BDividend YieldN/A1.65%5.37%4.21%P/E Ratio-55.709.3125.5619.50Price / Sales5.73393.22374.5098.59Price / Cash231.90151.9635.9456.46Price / Book15.994.667.855.49Net Income-$17.48M$31.15M$3.15B$248.35M7 Day Performance-1.06%2.47%1.01%2.01%1 Month Performance20.41%11.84%5.24%5.73%1 Year Performance46.13%4.13%38.87%18.07% Harrow Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HROWHarrow2.294 of 5 stars$31.15-1.3%$61.40+97.1%+45.8%$1.14B$199.61M-55.70182Positive NewsZLABZai Lab2.0497 of 5 stars$40.63-0.9%$47.37+16.6%+99.6%$4.48B$418.33M-14.671,950Insider TradeAnalyst RevisionAKROAkero Therapeutics3.6352 of 5 stars$55.75+0.2%$82.50+48.0%+134.2%$4.44BN/A-14.8730PBHPrestige Consumer Healthcare3.9367 of 5 stars$83.67-0.4%$93.33+11.6%+18.5%$4.13B$1.14B19.59540PTCTPTC Therapeutics4.7072 of 5 stars$51.87+1.2%$63.75+22.9%+39.1%$4.11B$1.77B-8.731,410CYTKCytokinetics4.2548 of 5 stars$33.78-1.7%$70.92+110.0%-37.4%$4.03B$19.22M-6.28250RYTMRhythm Pharmaceuticals4.4203 of 5 stars$62.39-0.8%$76.62+22.8%+45.7%$3.97B$136.86M-14.41140Positive NewsAnalyst ForecastACADACADIA Pharmaceuticals3.8367 of 5 stars$22.14+2.0%$26.79+21.0%+44.2%$3.71B$996.28M28.38510Trending NewsAnalyst ForecastMRUSMerus3.3777 of 5 stars$53.30-2.4%$85.83+61.0%-5.1%$3.69B$54.73M-13.4937Insider TradePRGOPerrigo4.5719 of 5 stars$26.71+0.2%$33.00+23.6%+4.1%$3.67B$4.34B-22.838,900Positive NewsRNAAvidity Biosciences2.2686 of 5 stars$29.80-5.0%$67.33+126.0%-23.2%$3.59B$8.93M-10.35190Analyst Forecast Related Companies and Tools Related Companies Zai Lab Alternatives Akero Therapeutics Alternatives Prestige Consumer Healthcare Alternatives PTC Therapeutics Alternatives Cytokinetics Alternatives Rhythm Pharmaceuticals Alternatives ACADIA Pharmaceuticals Alternatives Merus Alternatives Perrigo Alternatives Avidity Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HROW) was last updated on 6/26/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTop Picks for Trump’s Pro-Crypto America27 of crypto's most successful minds are about to pull back the curtain… Bitcoin has crushed its all-time h...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump: "Buy Stocks Now!" (Here's a Better Move)Trump: "Buy Stocks Now!" (Here's a Better Move) President Trump just announced from the Oval Office: "You b...Investors Alley | SponsoredTrump set to Boost Social Security Checks by 400%?If you're currently collecting—or planning to collect—Social Security benefits, there's an urgent development ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harrow, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harrow With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy HROW Stock Free HROW Stock Alerts